Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia.
Level 4 - case-series / case-control
Ex vivo case-control and non-randomized pre-post laboratory evaluation using human serum samples
PubMed 10525128 · doi:10.1016/s0021-9150(99)00166-5
What was done
LDL was isolated by sequential ultracentrifugation from the serum of normolipidemic controls and patients with type IIa, type IIb, or type IV hyperlipoproteinemia. Researchers evaluated LDL receptor binding affinity, LDL lipid composition (protein, triglycerides, cholesterol, phospholipids), particle size, and plasma cholesteryl ester transfer protein (CETP) activity. They also assessed changes in LDL characteristics and binding affinity following treatment with lipid-lowering agents (bezafibrate and probucol).
What was found
The abstract reports directional findings without numerical values or confidence intervals. Type IIa patients had LDL receptor affinity similar to normolipidemic controls. Patients with hypertriglyceridemia (type IIb and IV) showed reduced LDL receptor affinity that worsened with hypertriglyceridemia severity, even in mild hypertriglyceridemia regardless of cholesterol levels. Hypertriglyceridemic LDL was smaller, protein- and triglyceride-rich, and cholesterol- and phospholipid-poor. Alterations in composition and size were strongly associated with decreased receptor affinity. Drug treatment improved receptor affinity only when particle size and composition normalized. Plasma CETP activity was normal at baseline and did not change with drug-mediated normalization of LDL.
Why it matters
This study links hypertriglyceridemia and small, dense LDL particles to impaired LDL receptor clearance at the functional level. It provides a mechanistic rationale for lowering triglycerides to restore normal LDL particle kinetics and mitigate atherogenic risk.
Limits
The abstract does not state the sample size (n), patient demographics, or numerical data (such as binding affinities, particle diameters, or p-values). The drug treatment arm does not specify whether treatment was randomized, controlled, or blinded, nor does it report treatment duration or dosages. The study assesses ex vivo cellular binding rather than clinical cardiovascular outcomes.
Cited by
- supports Small LDL particles are cleared less efficiently by LDL receptors than larger LDL particles.